10 results about "Sialic acid binding" patented technology

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The present invention discloses a multi-site dendritic boronic acid functionalized magnetic nanomaterial and its preparation method and application, belonging to the field of biomaterial technology. The multi-site dendritic boronic acid functionalized magnetic nanomaterial is formed by polyethylenimine being coated on the surface of triferric oxide magnetic nanoparticles modified with sodium tripolyphosphate or sodium polyphosphate through electrostatic action to form polyethylenimine-modified triferric oxide magnetic nanoparticles, and then 4-carboxylphenylboronic acid is grafted onto the surface of the triferric oxide magnetic nanoparticles modified with polyethyleneimine through an amide reaction. Compared with the low binding ability of a single boronic acid site, the multi-site dendritic boronic acid functionalized magnetic nanomaterial in the present invention can more sensitively bind to sialic acid overexpressed by CTCs, thereby achieving a high capture rate of CTCs.

This invention discloses a sialyl polysaccharide-sialic acid-binding immunoglobulin-like lectin signaling pathway blocker, containing one or more N-acetylneuraminic acid derivatives, used to manufacture immunotherapy synergistic drugs or immunomodulatory drugs. The immunotherapy synergistic drugs are used in combination with immunotherapy drugs, and the immunomodulatory drugs are used to enhance the regulation of immunity.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

This invention discloses a method for preparing a fusion protein of sialic acid-binding immunoglobulin-like lectin 6 extracellular fragment and human immunoglobulin G1-Fc fragment, and its application, belonging to the field of biomedical technology. The fusion protein consists of a functional fragment of the Siglec-6 extracellular region linked to the Fc fragment of human IgG1 via a peptide linker. Its amino acid sequence is selected from one of SEQ ID No. 1, SEQ ID No. 2, or SEQ ID No. 3, or a variant with more than 90% homology to the above sequences and retaining the biological activity of Siglec-6. The preparation method includes: cloning the Siglec-6 fragment and the coding sequence of the Fc fragment, constructing a recombinant expression plasmid and transfecting it into mammalian cells to induce expression, and purifying the target protein by affinity chromatography. The fusion protein vcSig6-Fc of this invention has extremely high structural stability and ligand binding affinity, can significantly inhibit the expression of inflammatory factors and matrix-degrading enzymes in chondrocytes, and shows excellent performance in promoting COL2A1 expression, thus exhibiting good protective effects on articular cartilage and therapeutic effects on rheumatoid arthritis.

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such as the spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-S with high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and / or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

The application designs a method for in situ engineering of immune T cells by chemical means, and selects 4-(hydrazinocarbonyl) phenylboronic acid (PBA-Hz) as an immune cell engineering tool. Galactose oxidase (GAO) is used to oxidize the galactose and acetylgalactosamine at the end of the sugar chain on the surface of immune T cells to generate aldehyde groups, which are covalently connected with the hydrazine of PBA-Hz, and the engineered cell T PBA is obtained. PBA The phenylboronic acid on the surface of the cell can be specifically covalently combined with sialic acid on the tumor cell, so that the T PBA cell can better target the tumor cell for killing. At the same time, due to the blocking of the sialic acid site on the surface of the tumor cell, the sialic acid binding immunoglobulin-like lectin on the surface of the natural killer (NK) cell cannot bind to the sialic acid, thereby relieving the immune suppression on the NK cell. The application is a new type of engineered immune cell therapy, which has great application potential in cancer and other related diseases.

The invention discloses a nuclear track membrane based on a sialic acid nano-channel switch, and relates to a porous membrane electric signal sensor for detecting an Alzheimer's disease marker A beta oligomer. According to the invention, the surface of the nuclear track membrane is modified with nano particles with hydrophobic effect to slow down fibrosis of Abeta protein and prevent the Abeta protein from aggregating in holes to form protein fibers, and the annular gold nanoflowers are formed at the small hole end of the conical nuclear track membrane through a one-step reduction method; sulfhydrylated sialic acid is combined on the annular gold nanoflowers at the small hole ends of the conical nuclear pore membrane holes through gold-sulfur bonds, and sialic acid channels are formed; after the A beta oligomer is contacted with the sialic acid channel, the A beta oligomer and the sialic acid channel can generate specific recognition under the action of hydrogen bonds, and the sialic acid can generate conformational change under the action of synergistic hydrogen bonds, so that the effective aperture is reduced, and the ion flow in the aperture is changed to generate a characteristic electric signal. And a new direction is provided for the field of Alzheimer's disease examination.

Technologies for the prevention and / or treatment of pathogenic or microbial infections. Compositions relate to compositions, vaccines and methods comprising an immunogenic multiple antigen presenting system (MAPS), where two or more biotinylated polysaccharide antigens are interconnected or joined together by one or more fusion proteins comprising (i) a sialic acid binding domain (SBD) and (ii) a biotin-binding moiety (BBM), thereby facilitating the joining multiple polysaccharide antigens together in the complex to form a cross-linked MAPS-X immunogenic complex. The polysaccharide antigens that are linked can be on the same polysaccharide macromolecule or on distinct polysaccharide macromolecules.

Provided are a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec) -binding molecule possessing cis-trans converter properties upon binding to the Siglec; a vector comprising a nucleic acid molecule encoding an Siglec-binding molecule and a nucleic acid molecule encoding the Siglec; a host cell comprising the vector; an anti-CD22 antibody; a pharmaceutical composition comprising the anti-CD22 antibody and a pharmaceutically acceptable excipient, diluent or carrier; a method of preventing or treating an autoimmune disease or a neurological disease; and a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec)-binding molecule lacking cis-trans converter properties upon binding to the Siglec.